FDA
-
-
-
-
-
-
-
MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board
-
-
-
-
-
-
-
MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO
-
-
-
-
-
-
-
MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications
-
-
-
-
-
-
-
MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer
-
-
-
-
-
-
-
MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO
-
-
-
-
-
-
-
Today's most important initiations
-
-
-
-
-
-
-
MAIA Biotechnology Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

